Current and emerging treatment options for Peyronie’s disease

References

• MulhallJPCreechSDBoorjianSASubjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screeningJ Urol20041712350235315126819
   PubMed Web of Science ®Google Scholar
• BellaAJPerelmanMABrantWOLueTFPeyronie’s disease (CME)J Sex Med200741527153817970969
   PubMed Web of Science ®Google Scholar
• TaylorFLLevineLAPeyronie’s DiseaseUrol Clin North Am200734517534.vi17983892
   PubMed Web of Science ®Google Scholar
• RosenRCataniaJLueTImpact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controlsJ Sex Med200851977198418564146
   PubMed Web of Science ®Google Scholar
• ChungEDe YoungLBrockGBRat as an animal model for Peyronie’s disease research: a review of current methods and the peer-reviewed literatureInt J Impot Res20112323524121776004
   PubMed Web of Science ®Google Scholar
• UstaMFBivalacquaTJJabrenGWRelationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie’s diseaseJ Urol200417177577914713809
   PubMed Web of Science ®Google Scholar
• BjekicMDVlajinacHDSipeticSBMarinkovicJMRisk factors for Peyronie’s disease: a case-control studyBJU Int20069757057416469028
   PubMed Web of Science ®Google Scholar
• KadiogluATefekliAErolBOktarTTuncMTellalogluSA retrospective review of 307 men with Peyronie’s diseaseJ Urol20021681075107912187226
   PubMed Web of Science ®Google Scholar
• El-SakkaAIHassobaHMChuiRMBhatnagarRSDahiyaRLueTFAn animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expressionJ Urol1997158228422909366377
   PubMed Web of Science ®Google Scholar
• Del CarloMColeAALevineLADifferential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie’s plaque fibroblastsJ Urol20081792447245518433786
   PubMed Web of Science ®Google Scholar
• Gonzalez-CadavidNFRajferJTreatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategyNat Rev Urol2010721522120212516
   PubMed Web of Science ®Google Scholar
• LinCSLinGWangZMaddahSALueTFUpregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie’s diseaseBiochem Biophys Res Commun20022951014101912127997
   PubMed Web of Science ®Google Scholar
• HellstromWJMedical management of Peyronie’s diseaseJ Androl20093039740518974422
   PubMed Web of Science ®Google Scholar
• GelbardMKDoreyFJamesKThe natural history of Peyronie’s diseaseJ Urol1990144137613792231932
   PubMed Web of Science ®Google Scholar
• MulhallJPSchiffJGuhringPAn analysis of the natural history of Peyronie’s diseaseJ Urol200617521152118 discussion 211816697815
   PubMed Web of Science ®Google Scholar
• RalphDGonzalez-CadavidNMironeVThe management of Peyronie’s disease: evidence-based 2010 guidelinesJ Sex Med201072359237420497306
   PubMed Web of Science ®Google Scholar
• MontorsiFAdaikanGBecherESummary of the recommendations on sexual dysfunctions in menJ Sex Med201073572358821040491
   PubMed Web of Science ®Google Scholar
• GurSLiminMHellstromWJCurrent status and new developments in Peyronie’s disease: medical, minimally invasive and surgical treatment optionsExpert Opin Pharmacother20111293194421405946
   PubMed Web of Science ®Google Scholar
• AhujaSKSikkaSCHellstromWJStimulation of collagen production in an in vitro model for Peyronie’s diseaseInt J Impot Res19991120721210467520
   PubMed Web of Science ®Google Scholar
• SafarinejadMRHosseiniSYKolahiAAComparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized studyJ Urol200717813981403 discussion 140317706714
   PubMed Web of Science ®Google Scholar
• ShindelAWBullockTLBrandesSUrologist practice patterns in the management of Peyronie’s disease: a nationwide surveyJ Sex Med2008595496418042214
   PubMed Web of Science ®Google Scholar
• ZarafonetisCJHorraxTMTreatment of Peyronie’s disease with potassium para-aminobenzoate (potaba)J Urol19598177077213655401
   PubMed Web of Science ®Google Scholar
• TrostLWGurSHellstromWJPharmacological Management of Peyronie’s DiseaseDrugs20076752754517352513
   PubMed Web of Science ®Google Scholar
• ShahPJR GNAdibRSPryorJPA multicentre double-blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie’s diseaseProg Reprod Biol Med19836167
   Google Scholar
• WeidnerWHauckEWSchnitkerJPotassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized studyEur Urol200547530535 discussion 535–53615774254
   PubMed Web of Science ®Google Scholar
• AkkusECarrierSRehmanJBrezaJKadiogluALueTFIs colchicine effective in Peyronie’s disease? A pilot studyUrology1994442912958048212
   PubMed Web of Science ®Google Scholar
• KadiogluATefekliAKoksalTUstaMErolHTreatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcomeInt J Impot Res20001216917511045911
   PubMed Web of Science ®Google Scholar
• Prieto CastroRMLeva VallejoMERegueiro LopezJCCombined treatment with vitamin E and colchicine in the early stages of Peyronie’s diseaseBJU Int20039152252412656907
   PubMed Web of Science ®Google Scholar
• AkmanTSanliOUluocakNThe most commonly altered type of Peyronie’s disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal sideAndrologia201143283321219379
   PubMed Web of Science ®Google Scholar
• SafarinejadMRTherapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled studyInt J Impot Res20041623824314973528
   PubMed Web of Science ®Google Scholar
• ApaydinESemerciBKefiACikiliNGursanAMulazimogluNThe use of tamoxifen in the treatment of Peyronie’s diseaseInt J Impot Res199810S57
   PubMed Web of Science ®Google Scholar
• RalphDJBrooksMDBottazzoGFPryorJPThe treatment of Peyronie’s disease with tamoxifenBr J Urol1992706486511486392
   PubMedGoogle Scholar
• TelokenCRhodenELGrazziotinTMRosCTSogariPRSoutoCATamoxifen versus placebo in the treatment of Peyronie’s diseaseJ Urol19991622003200510569556
   PubMed Web of Science ®Google Scholar
• SmithJFWalshTJLueTFPeyronie’s disease: a critical appraisal of current diagnosis and treatmentInt J Impot Res20082044545918650828
   PubMed Web of Science ®Google Scholar
• BiagiottiGCavalliniGAcetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary reportBJU Int200188636711446848
   PubMed Web of Science ®Google Scholar
• CavalliniGBiagiottiGKoverechAVitaliGOral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s diseaseBJU Int20028989590012010235
   PubMed Web of Science ®Google Scholar
• KarlicHLohningerASupplementation of L-carnitine in athletes: does it make sense?Nutrition20042070971515212755
   PubMed Web of Science ®Google Scholar
• ValenteEGVernetDFerriniMGQianARajferJGonzalez-CadavidNFL-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast culturesNitric Oxide2003922924414996430
   PubMed Web of Science ®Google Scholar
• SmithJFShindelAWHuangYCPentoxifylline treatment and penile calcifications in men with Peyronie’s diseaseAsian J Androl20111332232521102473
   PubMed Web of Science ®Google Scholar
• ShindelAWLinGNingHPentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrixJ Sex Med201072077208520367772
   PubMed Web of Science ®Google Scholar
• LinGShindelAWBanieLPentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1J Sex Med201071787179720384945
   PubMed Web of Science ®Google Scholar
• SafarinejadMRAsgariMAHosseiniSYDadkhahFA double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s diseaseBJU Int201010624024819863517
   PubMed Web of Science ®Google Scholar
• LevineLALatchamsettyKCTreatment of erectile dysfunction in patients with Peyronie’s disease using sildenafil citrateInt J Impot Res20021447848212494281
   PubMed Web of Science ®Google Scholar
• LevineLAGreenfieldJMEstradaCRErectile dysfunction following surgical correction of Peyronie’s disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunctionJ Sex Med2005224124716422892
   PubMed Web of Science ®Google Scholar
• FerriniMGKovaneczINolazcoGRajferJGonzalez-CadavidNFEffects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s diseaseBJU Int20069762563316469038
   PubMed Web of Science ®Google Scholar
• ChungEDeyoungLBrockGBThe role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomesJ Sex Med201181472147721324095
   PubMed Web of Science ®Google Scholar
• PalmieriAImbimboCCretaMVerzePFuscoFMironeVTadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trialInt J Androl2011
   Google Scholar
• TranchantCBraunSWarterJM[Mechanism of action of glucocorticoids: role of lipocortins]Rev Neurol (Paris)19891458138182533385
   PubMed Web of Science ®Google Scholar
• BodnerHHowardAHKaplanJHPeyronle’s disease: cortisone-hyaluronidase-hydrocortisone therapyJ Urol19547240040313202225
   PubMed Web of Science ®Google Scholar
• WinterCCKhannaRPeyronie’s disease: results with dermo-jet injection of dexamethasoneJ Urol19751148989001195471
   PubMed Web of Science ®Google Scholar
• WilliamsGGreenNAThe non-surgical treatment of Peyronie’s diseaseBr J Urol1980523923957427014
   PubMedGoogle Scholar
• CipolloneGNicolaiMMastroprimianoGIantornoRLongeriDTenagliaR[Betamethasone versus placebo in Peyronie’s disease]Arch Ital Urol Androl1998701651689823662
   PubMedGoogle Scholar
• GelbardMKWalshRKaufmanJJCollagenase for Peyronie’s disease experimental studiesUrol Res1982101351406291216
   PubMed Web of Science ®Google Scholar
• GelbardMKLindnerAKaufmanJJThe use of collagenase in the treatment of Peyronie’s diseaseJ Urol19851342802832991611
   PubMed Web of Science ®Google Scholar
• HamiltonRGMintzGRGelbardMKHumoral immune responses in Peyronie’s disease patients receiving clostridial collagenase therapyJ Urol19861356416472868133
   PubMed Web of Science ®Google Scholar
• GelbardMKJamesKRiachPDoreyFCollagenase versus placebo in the treatment of Peyronie’s disease: a double-blind studyJ Urol199314956588417217
   PubMed Web of Science ®Google Scholar
• JordanGHThe use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled studyJ Sex Med2008518018718173766
   PubMed Web of Science ®Google Scholar
• RothMEickelbergOKohlerEErnePBlockLHCa2+ channel blockers modulate metabolism of collagens within the extracellular matrixProc Natl Acad Sci USA199693547854828643600
   PubMed Web of Science ®Google Scholar
• MulhallJPAndersonMSLubranoTShankeyTVPeyronie’s disease cell culture models: phenotypic, genotypic and functional analysesInt J Impot Res20021439740512454692
   PubMed Web of Science ®Google Scholar
• LevineLAMerrickPFLeeRCIntralesional verapamil injection for the treatment of Peyronie’s diseaseJ Urol1994151152215248189561
   PubMed Web of Science ®Google Scholar
• LasserAVandenbergTLVincentMJHellstromWJIntraplaque verapamil injection for treatment of Peyronie’s diseaseJ La State Med Soc19981504314349785755
   PubMedGoogle Scholar
• LevineLAGoldmanKEGreenfieldJMExperience with intraplaque injection of verapamil for Peyronie’s diseaseJ Urol2002168621625 discussion 625–62612131321
   PubMed Web of Science ®Google Scholar
• RehmanJBenetAMelmanAUse of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind studyUrology1998516206269586617
   PubMed Web of Science ®Google Scholar
• DuncanMRBermanBNseyoUORegulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gammaScand J Urol Nephrol19912589941651559
   PubMed Web of Science ®Google Scholar
• PolatOGulOOzbeyIOzdikiciMBayraktarYPeyronie’s disease: intralesional treatment with interferon alpha-2 A and evaluation of the results by magnetic resonance imagingInt Urol Nephrol1997294654719406006
   PubMedGoogle Scholar
• AhujaSBivalacquaTJCaseJVincentMSikkaSCHellstromWJA pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s diseaseJ Androl19992044444810452584
   PubMedGoogle Scholar
• AstorgaRCanteroOContrerasDIntralesional recombinant interferon alpha-2b in Peyronie’s diseaseArch Esp Urol20005366567111037665
   PubMedGoogle Scholar
• BrakeMLoertzerHHorschRKellerHTreatment of Peyronie’s disease with local interferon-alpha 2bBJU Int20018765465711350406
   PubMed Web of Science ®Google Scholar
• JudgeISWisniewskiZSIntralesional interferon in the treatment of Peyronie’s disease: a pilot studyBr J Urol19977940429043494
   PubMedGoogle Scholar
• HellstromWJKendirciMMaternRSingle-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s diseaseJ Urol200617639439816753449
   PubMed Web of Science ®Google Scholar
• GelbardMLindnerAChvapilMKaufmanJTopical beta-aminopropionitrile in the treatment of Peyronie’s diseaseJ Urol19831297467486842692
   PubMed Web of Science ®Google Scholar
• MillerHCArdizzoneJPeyronie disease treated with ultrasound and hydrocortisoneUrology1983215845856868230
   PubMed Web of Science ®Google Scholar
• MartinDJBadwanKParkerMMulhallJPTransdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albugineaJ Urol20021682483248512441945
   PubMed Web of Science ®Google Scholar
• FitchW3rdEasterlingWJTalbertRLBordovskyMJMosierMTopical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease--a placebo-controlled pilot studyJ Sex Med2007447748417367443
   PubMed Web of Science ®Google Scholar
• SinghJMaibachHITopical iontophoretic drug delivery in vivo: historical development, devices and future perspectivesDermatology19931872352388274778
   PubMed Web of Science ®Google Scholar
• LevineLAEstradaCRShouWColeATunica albuginea tissue analysis after electromotive drug administrationJ Urol20031691775177812686831
   PubMed Web of Science ®Google Scholar
• RiedlCRPlasEEngelhardtPDahaKPflugerHIontophoresis for treatment of Peyronie’s diseaseJ Urol2000163959910604323
   PubMed Web of Science ®Google Scholar
• Di StasiSMGiannantoniAStephenRLCapelliGGiurioliAJanniniEAVespasianiGA prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s diseaseJ Urol20041711605160815017231
   PubMed Web of Science ®Google Scholar
• Di StasiSMGiannantoniACapelliGTransdermal electromotive administration of verapamil and dexamethasone for Peyronie’s diseaseBJU Int20039182582912780842
   PubMed Web of Science ®Google Scholar
• GreenfieldJMShahSJLevineLAVerapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trialJ Urol200717797297517296390
   PubMed Web of Science ®Google Scholar
• SkolarikosAAlargofERigasADeliveliotisCKonstantinidisEShockwave therapy as first-line treatment for Peyronie’s disease: a prospective studyJ Endourol200519111415735375
   PubMed Web of Science ®Google Scholar
• SrirangamSJManikandanRHussainJCollinsGNO’ReillyPHLong-term results of extracorporeal shockwave therapy for Peyronie’s diseaseJ Endourol20062088088417144855
   PubMed Web of Science ®Google Scholar
• MichelMSPtaschnykTMusialAObjective and subjective changes in patients with Peyronie’s disease after management with shockwave therapyJ Endourol2003174144 discussion 4412639361
   PubMed Web of Science ®Google Scholar
• StrebelRT SSSautterTHauriDExtracorporeal shock wave therapy for Peyronie’s disease does not correct penile deformityInt J Impot Res20041644845114973523
   PubMed Web of Science ®Google Scholar
• HauckEWHauptmannABschleipferTSchmelzHUAltinkilicBMWeidnerWQuestionable efficacy of extracorporeal shock wave therapy for Peyronie’s disease: results of a prospective approachJ Urol200417129629914665898
   PubMed Web of Science ®Google Scholar
• HauckEWMuellerUOBschleipferTSchmelzHUDiemerTWeidnerWExtracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trialsJ Urol200417174074514713800
   PubMed Web of Science ®Google Scholar
• ChitaleSMorseyMSwiftLSethiaKLimited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trialBJU Int20101061352135620438568
   PubMed Web of Science ®Google Scholar
• PalmieriAImbimboCLongoNA first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s diseaseEur Urol20095636336919473751
   PubMed Web of Science ®Google Scholar
• HauckEWDiemerTSchmelzHUWeidnerWA critical analysis of non-surgical treatment of Peyronie’s diseaseEur Urol20064998799716698449
   PubMed Web of Science ®Google Scholar
• TaylorFLLevineLANon-surgical therapy of Peyronie’s diseaseAsian J Androl200810798718087647
   PubMed Web of Science ®Google Scholar
• LevineLANewellMTaylorFLPenile traction therapy for treatment of Peyronie’s disease: a single-center pilot studyJ Sex Med200851468147318373527
   PubMed Web of Science ®Google Scholar
• GonteroPDi MarcoMGiubileiGUse of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective studyJ Sex Med2009655856619138361
   PubMed Web of Science ®Google Scholar
• RaheemAAGaraffaGRaheemTAThe role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s diseaseBJU Int20101061178118020438558
   PubMed Web of Science ®Google Scholar
• RalphDJLong-term results of the surgical treatment of Peyronie’s disease with plaque incision and graftingAsian J Androl20111379721785446
   PubMed Web of Science ®Google Scholar
• DjinovicRPenile corporoplasty in Peyronie’s disease: which technique, which graft?Curr Opin Urol20112147047721941186
   PubMed Web of Science ®Google Scholar
• TaylorFLLevineLASurgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow upJ Sex Med2008522212228 discussion 2229–223018637996
   PubMed Web of Science ®Google Scholar
• SerefogluECHellstromWJTreatment of Peyronie’s Disease: 2012 UpdateCurr Urol Rep20111244445221818660
   PubMedGoogle Scholar
• KadiogluAKucukdurmazFSanliOCurrent status of the surgical management of Peyronie’s diseaseNat Rev Urol201189510621304544
   PubMed Web of Science ®Google Scholar
• EssedESchroederFHNew surgical treatment for Peyronie diseaseUrology1985255825874012950
   PubMed Web of Science ®Google Scholar
• YachiaDModified corporoplasty for the treatment of penile curvatureJ Urol199014380822294269
   PubMed Web of Science ®Google Scholar
• DaitchJAAngermeierKWMontagueDKModified corporoplasty for penile curvature: long-term results and patient satisfactionJ Urol19991622006200910569557
   PubMed Web of Science ®Google Scholar
• RehmanJBenetAMinskyLSMelmanAResults of surgical treatment for abnormal penile curvature: Peyronie’s disease and congenital deviation by modified Nesbit plication (tunical shaving and plication)J Urol1997157128812919120923
   PubMed Web of Science ®Google Scholar
• RalphDJal-AkraaMPryorJPThe Nesbit operation for Peyronie’s disease: 16-year experienceJ Urol1995154136213637658538
   PubMed Web of Science ®Google Scholar
• GholamiSSLueTFCorrection of penile curvature using the 16-dot plication technique: a review of 132 patientsJ Urol20021672066206911956440
   PubMed Web of Science ®Google Scholar
• SyedAHAbbasiZHargreaveTBNesbit procedure for disabling Peyronie’s curvature: a median follow-up of 84 monthsUrology200361999100312736023
   PubMed Web of Science ®Google Scholar
• SavocaGScieriFPietropaoloFGaraffaGBelgranoEStraightening corporoplasty for Peyronie’s disease: a review of 218 patients with median follow-up of 89 monthsEur Urol462004610614 discussion 613–61415474271
   PubMed Web of Science ®Google Scholar
• RolleLTamagnoneATimpanoMDestefanisPFioriCCerutiCFontanaDThe Nesbit operation for penile curvature: an easy and effective technical modificationJ Urol2005173171173 discussion 173–17415592068
   PubMed Web of Science ®Google Scholar
• BellaAJBeasleyKAObiedABrockGBMinimally invasive intracorporeal incision of Peyronie’s plaque: initial experiences with a new techniqueUrology20066885285717070366
   PubMed Web of Science ®Google Scholar
• GreenfieldJMLucasSLevineLAFactors affecting the loss of length associated with tunica albuginea plication for correction of penile curvatureJ Urol175200617523824116406919
   PubMed Web of Science ®Google Scholar
• RichardsonBPinskyMRHellstromWJIncision and grafting for severe Peyronie’s disease (CME)J Sex Med2009620842087 quiz 208819682225
   PubMed Web of Science ®Google Scholar
• Moncada-IribarrenI JJMartinez-SalamancaJICabelloRHernandezCManaging penile shortening after Peyronie’s disease surgeryJ Urol200717725217162057
   PubMed Web of Science ®Google Scholar
• DublinNStewartLHOral complications after buccal mucosal graft harvest for urethroplastyBJU Int20049486786915476524
   PubMed Web of Science ®Google Scholar
• SantucciRABarberTDResorbable extracellular matrix grafts in urologic reconstructionInt Braz J Urol20053119220315992421
   PubMedGoogle Scholar
• SievertKDTanaghoEAOrgan-specific acellular matrix for reconstruction of the urinary tractWorld J Urol200018192510766039
   PubMed Web of Science ®Google Scholar
• BreyerBNBrantWOGarciaMMBellaAJLueTFComplications of porcine small intestine submucosa graft for Peyronie’s diseaseJ Urol200717758959117222639
   PubMed Web of Science ®Google Scholar
• TornehlCKCarsonCCSurgical alternatives for treating Peyronie’s diseaseBJU Int20049477478315476507
   PubMed Web of Science ®Google Scholar
• KendirciMHellstromWJCritical analysis of surgery for Peyronie’s diseaseCurr Opin Urol20041438138815626883
   PubMed Web of Science ®Google Scholar
• LeungwattanakijSBivalacquaTJReddySHellstromWJLong-term follow-up on use of pericardial graft in the surgical management of Peyronie’s diseaseInt J Impot Res20011318318611525318
   PubMed Web of Science ®Google Scholar
• MulhallJAndersonMParkerMA surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: functional and satisfaction outcomesJ Sex Med2005213213816422916
   PubMed Web of Science ®Google Scholar
• WilsonSKDelkJR2ndA new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesisJ Urol1994152112111238072079
   PubMed Web of Science ®Google Scholar
• WilsonSKClevesMADelkJR2ndLong-term followup of treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesisJ Urol200116582582911176479
   PubMed Web of Science ®Google Scholar